[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/","commit":"91a4bba51c","date":"2026-09-10","author":"Jude Gomila","message":"Fourteen orphan products now linked from their targets and cancers (ALK, EGFR, ROS1, ER, FOLR1 inhibitors and tracers; myeloma, prostate, gl","file":"src/data/targets.ts","type":"changed","fields":[{"field":"drugs","after":"[\"dacomitinib\", \"mobocertinib\"]"}]},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/targets.ts","type":"changed","fields":[{"field":"biology","before":"\"Receptor tyrosine kinase activating RAS-MAPK and PI3K-AKT. Exon 20 insertions need dedicated drugs.\"","after":"\"EGFR is a receptor tyrosine kinase activating RAS-MAPK and PI3K-AKT. Exon 20 insertions need dedicated drugs.\""}]},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/","commit":"cebb34a709","date":"2026-09-08","author":"Jude Gomila","message":"Guideline mapping on every standard-of-care row; sourced biomarker prevalence for 59 targets; GuidelineChip, PrevalenceTable, CancerPrevalen","file":"src/data/targets.ts","type":"changed","fields":[{"field":"prevalence","after":"[\n      { cancerId: \"nsclc\", pct: \"10-15\", measure: \"Activating mutation (US/Europe)\", source: \"https://www.cbioportal.org/study/summary?id=luad_tcga_pan_can_atlas_2018\", note: \"40-50% in East Asian adenocarcinoma\" },..."}]}]